Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

16.94 +0.07 (+0.41%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
27 28 Next >
Teva Pharmaceutical To Rally Around 58%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Beyond The Numbers: 8 Analysts Discuss Teva Pharmaceutical Indus Stock
Via Benzinga
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month. 
Via InvestorPlace
Teva Pharmaceutical Industries (TEVA) Q4 2023 Earnings Call Transcript
TEVA earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Boeing Posts Upbeat Results, Joins Stryker, Automatic Data Processing And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mostly lower, with the Nasdaq Composite falling over 200 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
A Preview Of Teva Pharmaceutical Indus's Earnings
Via Benzinga
Generic Drug Player Teva Pharma To Divest Its Active Pharmaceutical Ingredient Business, Q4 Earnings Surpass Estimates
Teva Pharmaceutical surpasses Q4 2023 sales expectations, reporting $4.46 billion. Teva plans to divest API business for revenue optimization. Outlook for FY 2024. 
Via Benzinga
Teva Sinks On Lackluster Profit Outlook Despite Walloping Quarterly Projections
Teva Pharmaceutical easily beat fourth-quarter views, but its 2024 profit guidance left something to be desired. 
Via Investor's Business Daily
Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser
The record run of the market faces risk as the big tech earnings season got off to a negative start, casting cloud on profit outlook. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Teva Reports Growth in Fourth Quarter and Full Year 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy
From Teva Pharmaceutical Industries Limited
Via Business Wire
Stocks Mixed Ahead Of Big Tech Earnings
Stocks are a mixed bag this afternoon, following the start of the Federal Reserve's two-day policy meeting. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Enphase Energy To Rally Over 35%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Earnings Scheduled For January 31, 2024
Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion. 
Via Benzinga
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
In-Depth Examination Of 4 Analyst Recommendations For Teva Pharmaceutical Indus
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Healthcare Giant Eli Lilly Under FDA Lens Again For Manufacturing Lapses
Eli Lilly faces FDA scrutiny with eight deficiencies at its Branchburg plant, raising concerns on Emgality's manufacturing. 
Via Benzinga
Exposures Product Safety
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease. 
Via Investor's Business Daily
3 No-Brainer Stocks to Buy With $20 Right Now
You don't need a mountain of cash to begin building your wealth on Wall Street. 
Via The Motley Fool
Cramer Says This Major Healthcare Stock Is 'Ridiculously Cheap And Doing So Many Great Things'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Realty Income (NYSE: O) and recommends staying with it. "It’s a very steady story," he noted. 
Via Benzinga
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
My 5 Largest Portfolio Holdings for 2024
This mix of growth and value stocks appears set to outperform -- and hopefully makes me a lot richer in the process. 
Via The Motley Fool
Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
From Teva Pharmaceutical Industries Limited
Via Business Wire
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity
From Teva Pharmaceutical Industries Limited
Via Business Wire
Venue Turmoil: Pharma Companies Oppose States' Bid to Relocate Price-Fixing Cases
Major pharmaceutical firms, including generic manufacturers such as Teva Pharmaceutical Industries Limited (NYSE: TEVA), Sandoz Group (OTC:  
Via Benzinga
Supreme Court Decision Looms Over Purdue Pharma's $6B Opioid Settlement And Sackler Family Immunity
The fate of a $6 billion bankruptcy settlement involving Purdue Pharma, the maker of the powerful and addictive pain medication OxyContin, hangs in th 
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
MarketBeat Week in Review – 11/27 - 12/1
Stocks closed the week at or near yearly highs after subdued inflation numbers suggest the Federal Reserve will continue to pause on raising rates 
Via MarketBeat
Topics Economy Stocks
Exposures Economy Interest Rates US Equities
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
From Teva Pharmaceutical Industries Limited
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS